1. Signifor [prescribing information] East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2012.
2. Colao A, Petersenn S, Newell-Price J, et al. A 12-Month Phase 3 Study of Pasireotide in Cushings Disease. N Engl J Med 2012;366:914-24.
3. Biller BM, Grossman AB, Stewart PM, et al. Treatment of Adrenocorticotropin-Dependent Cushings Syndrome: A Consensus Statement. J Clin Endocrinol Metab. July 2008, 93(7):24542462.
4. Micromedex Healthcare Series [Internet Database]. Greenwood, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed June 12, 2014.